West Pharmaceutical Services (WPS) Stock Forecast & Price Target
WPS Analyst Ratings
Strong Buy
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to West Pharmaceutical Services in the past 3 months
WPS Stock 12 Month Forecast
Average Price Target
CHF 394.39▲(0.00% Upside)Based on 6 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is CHF 394.39 with a high forecast of CHF 412.40 and a low forecast of CHF 329.92. The average price target represents a ― change from the last price of ―.
Highest Price TargetHighestCHF 412.40Average Price TargetCHF 394.39Lowest Price TargetLowestCHF 329.92
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Luke Sergott | Barclays | CHF 362.91→CHF 412.40 | buy | ― | Reiterated | 10/30/26 | ||
| Joanne Wuensch | Citi | CHF 339.82→CHF 407.45 | buy | ― | Reiterated | 10/30/26 | ||
 Unknown AnalystNot Ranked | UBS | CHF 358.79→CHF 408.28 | buy | ― | Reiterated | 10/30/26 | ||
| Daniel Markowitz CFA | Evercore ISI | CHF 362.91→CHF 395.91 | buy | ― | Reiterated | 10/30/26 | ||
| Brendan Smith | TD Cowen | CHF 346.42→CHF 412.40 | buy | ― | Reiterated | 10/29/26 | ||
| Kallum Titchmarsh | Morgan Stanley | CHF 301.05→CHF 329.92 | buy | ― | Upgraded | 09/22/26 | ||
| Michael Ryskin | Bank of America Securities | CHF 338.17 | buy | ― | Reiterated | 07/24/26 | ||
| Matt Larew | William Blair | ― | buy | ― | Reiterated | 07/23/26 | ||
| Curtis Moiles | Exane BNP Paribas | CHF 368.69 | buy | ― | Initiated | 07/13/26 | ||
| Paul Knight | KeyBanc | CHF 288.68→CHF 321.67 | buy | ― | Reiterated | 07/02/26 | ||
| Michael Polark | Wolfe Research | CHF 309.30 | buy | ― | Assigned | 06/01/26 | ||
| Justin Bowers | Deutsche Bank | CHF 255.69→CHF 259.81 | buy | ― | Reiterated | 02/13/26 | ||
| Dan Leonard | RBC Capital | CHF 292.81→CHF 280.43 | buy | ― | Reiterated | 02/13/26 | ||
| David Windley | Jefferies | CHF 301.05→CHF 243.32 | buy | ― | Reiterated | 02/10/26 | ||
| Nico Chen | DBS | CHF 263.94 | buy | ― | Reiterated | 01/28/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Luke Sergott | 10/30/26 | CHF 362.91→CHF 412.40 | buy | ― | Reiterated | Barclays | ||
| Joanne Wuensch | 10/30/26 | CHF 339.82→CHF 407.45 | buy | ― | Reiterated | Citi | ||
| Unknown AnalystNot Ranked | 10/30/26 | CHF 358.79→CHF 408.28 | buy | ― | Reiterated | UBS | ||
| Daniel Markowitz CFA | 10/30/26 | CHF 362.91→CHF 395.91 | buy | ― | Reiterated | Evercore ISI | ||
| Brendan Smith | 10/29/26 | CHF 346.42→CHF 412.40 | buy | ― | Reiterated | TD Cowen | ||
| Kallum Titchmarsh | 09/22/26 | CHF 301.05→CHF 329.92 | buy | ― | Upgraded | Morgan Stanley | ||
| Michael Ryskin | 07/24/26 | CHF 338.17 | buy | ― | Reiterated | Bank of America Securities | ||
| Matt Larew | 07/23/26 | ― | buy | ― | Reiterated | William Blair | ||
| Curtis Moiles | 07/13/26 | CHF 368.69 | buy | ― | Initiated | Exane BNP Paribas | ||
| Paul Knight | 07/02/26 | CHF 288.68→CHF 321.67 | buy | ― | Reiterated | KeyBanc | ||
| Michael Polark | 06/01/26 | CHF 309.30 | buy | ― | Assigned | Wolfe Research | ||
| Justin Bowers | 02/13/26 | CHF 255.69→CHF 259.81 | buy | ― | Reiterated | Deutsche Bank | ||
| Dan Leonard | 02/13/26 | CHF 292.81→CHF 280.43 | buy | ― | Reiterated | RBC Capital | ||
| David Windley | 02/10/26 | CHF 301.05→CHF 243.32 | buy | ― | Reiterated | Jefferies | ||
| Nico Chen | 01/28/26 | CHF 263.94 | buy | ― | Reiterated | DBS |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering West Pharmaceutical Services
3 Months
Success Rate8/10 ratings generated profit
80%
Average Return
+14.30%
Copying Matt Larew's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +14.30% per trade.
1 Year
Success Rate5/5 ratings generated profit
100%
Average Return
+36.08%
Copying Brendan Smith's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +36.08% per trade.
2 Years
Success Rate6/6 ratings generated profit
100%
Average Return
+59.88%
Copying Dan Leonard's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +59.88% per trade.
WPS Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 17 | 14 | 13 | 10 | 9 |
| Hold | 5 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 22 | 16 | 15 | 11 | 10 |
In the current month, WPS has received 9 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. WPS average Analyst price target in the past 3 months is 394.39.
WPS Financial Forecast
HighCHF 1.91
ConsensusCHF 1.88
LowCHF 1.84
WPS Earnings Forecast
Next quarter’s earnings estimate for WPS is CHF 1.88 with a range of CHF 1.84 to CHF 1.91. The previous quarter’s EPS was CHF 2.19. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF 683M
ConsensusCHF 680M
LowCHF 676M
WPS Sales Forecast
Next quarter’s sales forecast for WPS is CHF 679.63M with a range of CHF 676.37M to CHF 682.97M. The previous quarter’s sales results were CHF 720.37M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
WPS Stock Forecast FAQ
What is CH:WPS’s average 12-month price target, according to analysts?
Based on analyst ratings, West Pharmaceutical Services’s 12-month average price target is CHF394.39.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is West Pharmaceutical Services a Buy, Sell or Hold?
West Pharmaceutical Services has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is West Pharmaceutical Services’s share price target?
The average share price target for West Pharmaceutical Services is CHF394.39. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF412.40, and the lowest forecast is CHF329.92. The average share price target represents a 0.00% increase from the current price of ―.
What do analysts say about West Pharmaceutical Services?
West Pharmaceutical Services’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of West Pharmaceutical Services?
To buy shares of CH:WPS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
